<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002119</url>
  </required_header>
  <id_info>
    <org_study_id>222A</org_study_id>
    <secondary_id>WF10-92-US-001</secondary_id>
    <nct_id>NCT00002119</nct_id>
  </id_info>
  <brief_title>A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection</brief_title>
  <official_title>A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxo Chemie GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution
      administered to patients with HIV infection. To evaluate the potential anti-HIV activity of
      TCDO.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WF10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Required:

          -  Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with
             CD4 count &lt;= 200 cells/mm3.

        Allowed:

          -  PCP prophylaxis with aerosolized pentamidine in patients with CD4 count &gt; 200
             cells/mm3, only at the discretion of the treating physician.

        Patients must have:

          -  HIV positivity.

          -  Absolute CD4 count of 150 - 500 cells/mm3.

          -  At least 6 months of prior zidovudine therapy.

          -  No active opportunistic infection requiring ongoing therapy.

          -  Life expectancy of at least 6 months.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Neoplasm other than basal cell carcinoma of the skin.

          -  Clinically significant cardiac disease.

          -  Abnormal neurological status by a standardized assessment including strength, reflex
             testing, and sensory testing.

          -  Unwilling to comply with protocol requirements.

        Patients with the following prior conditions are excluded:

        History of myocardial infarction or arrhythmias.

        Prior Medication:

        Excluded within 2 weeks prior to study entry:

          -  Antiretroviral agent or interferon.

          -  Systemic biologic response modifiers, corticosteroids, cytotoxic chemotherapeutic
             agents, or other drugs that can cause neutropenia or significant nephrotoxicity.

          -  Rifampin or rifampin derivatives.

          -  Systemic anti-infectives.

        Required:

          -  At least 6 months of prior zidovudine. Active drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oncol Med Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Busch HW, Christensen S, Reichelt D, Jahn S, Zidek W. Treatment of HIV-infected patients with advanced symptomatic disease with WF10 solution (TCDO). Int Conf AIDS. 1994 Aug 7-12;10(1):204 (abstract no PB0245)</citation>
  </reference>
  <reference>
    <citation>Kahn JO, McGrath MS, Ching OM, Kuhne FW. A single center, phase 2 study evaluating the effects of WF10. Int Conf AIDS. 1998;12:349 (abstract no 22423)</citation>
  </reference>
  <reference>
    <citation>Raffanti SP, Schaffner W, Federspiel CF, Blackwell RB, Ching OA, KÃ¼hne FW. Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection. 1998 Jul-Aug;26(4):202-7.</citation>
    <PMID>9717676</PMID>
  </reference>
  <verification_date>March 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

